Parallel whole genome and transcriptome sequencing identified a cell motility driver mutation in the LPAR1 gene, and this combinatorial approach may be leveraged for precision therapy in patients with cancer by targeting expressed driver mutations. The gene discussed is LPAR1; the disease is cancer.